Search Results

You are looking at 81 - 90 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Pediatric Hodgkin Lymphoma, Version 3.2021

Jamie E. Flerlage, Susan M. Hiniker, Saro Armenian, Ellen C. Benya, Adam J. Bobbey, Vivian Chang, Stacy Cooper, Don W. Coulter, Branko Cuglievan, Bradford S. Hoppe, Leidy Isenalumhe, Kara Kelly, Leslie Kersun, Adam J. Lamble, Nicole A. Larrier, Jeffrey Magee, Kwadwo Oduro, Martha Pacheco, Anita P. Price, Kenneth B. Roberts, Christine M. Smith, Aliyah R. Sohani, Erin M. Trovillion, Emily Walling, Ana C. Xavier, Jennifer L. Burns, and Mallory Campbell

. During follow-up, scans should only be obtained if there is clinical concern for relapse, or for up to 2 years. Principles of RT RT can be delivered with photons, electrons, or protons, depending on clinical circumstances (see PHL-F 1, 2, and 3 of 4

Full access

Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification

Presented by: Natalie S. Callander

updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma outline factors considered as high risk for disease progression or relapse in patients with newly diagnosed disease. 1 Dr. Callander particularly highlighted the

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Christos Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley Somer, Jeffrey Sosman, Mary A. Dwyer, and Angela D. Motter

nonmetastatic primary RCC typically consists of surgery (ie, nephrectomy). Systemic therapy options for patients with relapsed or stage IV disease include kinase inhibitors, mTOR inhibitors, and monoclonal antibodies against VEGF, PD-1, or PD-L1. Recommended

Full access

Resistance to Imatinib: Mechanisms and Management

Michael Deininger

) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) [abstract] . Blood. 2004 ; 104 : 10a . 48 Gumireddy K Baker SJ Cosenza SC . A non

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

targeted therapies, such as BTK inhibitors, PI3K inhibitors, EZH2 inhibitors, antibody–drug conjugates, anti-CD19 CAR T-cell therapies, and other CD19-directed targeted therapies, have emerged as effective treatment options for relapsed/refractory (R

Full access

Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

Mathias Rummel

, many randomized studies indicate that combining rituximab with chemotherapy provides a substantial benefit compared with chemotherapy alone, in both the front-line and relapsed/refractory settings. 14 , 15 In a meta-analysis of patients with newly

Full access

Biologic Agents in the Management of Hodgkin Lymphoma

Armin Rashidi and Nancy L. Bartlett

patients with newly diagnosed classical Hodgkin lymphoma (HL) have an excellent prognosis after multiagent chemotherapy with or without radiation. Biologic agents offer highly desirable approaches to patients with relapsed or refractory disease in which the

Full access

Melanoma, Version 4.2014

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho

reduce nodal relapse is a source of ongoing controversy because of the lack of survival benefits and concerns of late toxicities. With the advent of targeted therapy for advanced melanoma, there is increasing appreciation that the incidence of specific

Full access

Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes

H. Joachim Deeg and Marcos de Lima

-high-risk cytogenetics according to the revised IPSS-R criteria, have a very poor outcome after HCT, primarily related to relapse, which may occur in as many as 40% of patients. 26 This may be even more of an issue in older patients because of the use of RIC regimens

Full access

The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma

William I. Bensinger

the EBMT. European Group for Blood and Marrow Transplant . Br J Haematol 1998 ; 102 : 1115 – 1123 . 24 Corradini P Cavo M Lokhorst H . Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse